Stock Track | Zenas BioPharma Soars 9.17% on CEO Share Purchase and Phase 3 Trial Progress

Stock Track

05/19

Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that boosted investor confidence.

The stock's upward movement was driven in part by news that CEO Leon O. Moulder Jr. purchased 60,000 common shares for approximately $1.01 million at a weighted average price of $16.88. This substantial insider buying, disclosed shortly before the price movement, signaled strong confidence from the company's leadership in Zenas BioPharma's future prospects.

Additionally, the company announced advancements in its Phase 3 clinical trial for orelabrutinib, targeting the challenging multiple sclerosis segment. This positive development in the company's pipeline of transformative therapies for autoimmune diseases further contributed to the bullish sentiment among investors during the trading session.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1144972324"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144972324\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144972324?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 09:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144972324","market":"sg","top_or_hot":-1,"title":"Stock Track | Zenas BioPharma Soars 9.17% on CEO Share Purchase and Phase 3 Trial Progress","media":"Stock Track","content":"<p>Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that boosted investor confidence.</p><p>The stock's upward movement was driven in part by news that CEO Leon O. Moulder Jr. purchased 60,000 common shares for approximately $1.01 million at a weighted average price of $16.88. This substantial insider buying, disclosed shortly before the price movement, signaled strong confidence from the company's leadership in Zenas BioPharma's future prospects.</p><p>Additionally, the company announced advancements in its Phase 3 clinical trial for orelabrutinib, targeting the challenging multiple sclerosis segment. This positive development in the company's pipeline of transformative therapies for autoimmune diseases further contributed to the bullish sentiment among investors during the trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Zenas BioPharma Soars 9.17% on CEO Share Purchase and Phase 3 Trial Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Zenas BioPharma Soars 9.17% on CEO Share Purchase and Phase 3 Trial Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-19 09:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that boosted investor confidence.</p><p>The stock's upward movement was driven in part by news that CEO Leon O. Moulder Jr. purchased 60,000 common shares for approximately $1.01 million at a weighted average price of $16.88. This substantial insider buying, disclosed shortly before the price movement, signaled strong confidence from the company's leadership in Zenas BioPharma's future prospects.</p><p>Additionally, the company announced advancements in its Phase 3 clinical trial for orelabrutinib, targeting the challenging multiple sclerosis segment. This positive development in the company's pipeline of transformative therapies for autoimmune diseases further contributed to the bullish sentiment among investors during the trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZBIO","symbol_name":"Zenas BioPharma Inc.","start_time":0,"source_url":"","article_id":"1144972324","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144972324","pubTimestamp":1779154765,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZBIO":"Zenas BioPharma Inc."},"translate_title":"个股追踪|Zenas BioPharma因CEO购股及3期试验进展大涨9.17%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBIO":1},"content_text":"Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that boosted investor confidence.The stock's upward movement was driven in part by news that CEO Leon O. Moulder Jr. purchased 60,000 common shares for approximately $1.01 million at a weighted average price of $16.88. This substantial insider buying, disclosed shortly before the price movement, signaled strong confidence from the company's leadership in Zenas BioPharma's future prospects.Additionally, the company announced advancements in its Phase 3 clinical trial for orelabrutinib, targeting the challenging multiple sclerosis segment. This positive development in the company's pipeline of transformative therapies for autoimmune diseases further contributed to the bullish sentiment among investors during the trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}